C.J.A. Punt

PCN12 EXPLORING THE ROLE OF OUTCOMES RESEARCH IN DUTCH REIMBURSEMENT POLICY: REAL-WORLD PHARMACOECONOMICS OF OXALIPLATIN IN STAGE III COLON CANCER

multi-center, observational study on GIST patients treated with Imatinib between the availability on the French Market and the end of the 2008. Centers were randomly selected in national files of oncologists, gastrointestinal surgeons and specialists. The planned follow-up duration was three years. A case report form had to be completed at inclusion and during each follow-up visits. Quality of life was assessed using QLQC30 and SF36 questionnaires. RESULTS: Thirty on 51 selected centers enrolled at least one patient and 139 patients were included (as of June 2009). The median age of disease onset was 58 years (range 21–86). 42% were metastatic at diagnosis. Primary tumors were most often stomach (48%), or bowel (34%). At diagnosis 86% of patients had a tumor size over 5 cm. 68% of patients had surgery of the primary tumor before starting Imatinib. 68% of patients were considered as high risk of relapse according the Miettinen classification. For 99% of the patients, Imatinib was given at an initial dosage of 400 mg, 1% at 300 mg. Compliance was superior to 90% for 99% of patients. With a median follow-up of 2.1 years, two-years overall survival from first treatment with Imatinib was 83.9% (CI95%: [74.5%–90.1%]). CONCLUSIONS: EPIGIST is still an ongoing survey. Current results confirm previous published data on survival in GIST treated with Imatinib in an unselected cohort of patients outside of a clinical trial.